Combination treatment for advanced liver cancer with diabetes
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of medications (a diabetes drug, chemotherapy, targeted therapy, and immunotherapy) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this combination can help control the cancer while also addressing nerve damage from diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes (type 1 or type 2) and advanced liver cancer that cannot be surgically removed (stage C).
- You are between 18 and 80 years old.
- You have relatively good liver function (a score of 7 or less on the Child-Pugh scale) and are generally able to care for yourself (ECOG score 0 or 1).
- You have not had other cancers before.
- You are not pregnant or breastfeeding.
- You do not have severe liver, heart, or kidney problems, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of three drugs for people with advanced liver cancer whose disease got worse after their first treatment. The goal is to see if this new mix can help control the cancer better and give patients more time.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.